Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:5/28/2008

PALO ALTO, Calif., May 28 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 31 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 151,800 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. CV Therapeutics also has other cl
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... . , Electrical ... a new kind of building block for digital integrated ... be based on three-dimensional arrangements of nanometer-scale magnets instead ... semiconductor industry CMOS fabrication of silicon chips ... the University of Notre Dame are exploring "magnetic computing" ...
(Date:9/30/2014)... , Sept. 30, 2014 Report ... segments with highest potential revenues Do you want ... report gives you revenue predictions for those biological ... those therapies you find financial data, R&D trends, ... you get sales forecasts to 2024 at overall ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Over the ... primarily due to rising R&D budgets and increased acceptance ... fast growing pharmaceutical and biotechnology industries are also catalyzing ... laboratory filtration market is expected to grow at a ... is estimated to be worth $2,532.6 million by 2019. ...
(Date:9/30/2014)... Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: ... it has received a Canadian Patent for Inhibition ... This patent includes claims using thymosin beta 4, ... peptides for these purposes.  The patent will expire ... Inc. ( www.regenerx.com ) RegeneRx ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... solopack Gold cells reduce the time and effort needed ... Amy Duncan Bruce,Jerpseth Alan Greener ,Stratagene ... , strain* in an easy-to-use, single-reaction format ... 9 transformants/g of,supercoiled DNA or the competent efficiency ...
... purification from a more versatile vector , ... ,Epitope Tagging in E. coli , Katherine Felts ... ,Stratagene , Stratagene has improved the Affinity ... vector. This new E. coli cloning and expression,vector ...
... data with the MutaTrak electronic notebook , G. ... Hamovitch Doug Schroeder ,Solana Consulting Group, Solana Beach, ... record Big,Blue transgenic rodent ... entered in a logical order and updated easily,as an ...
Cached Biology Technology:XL10-Gold Cells Supplied in New Single-Reaction Format 2XL10-Gold Cells Supplied in New Single-Reaction Format 3XL10-Gold Cells Supplied in New Single-Reaction Format 4High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 2High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 3High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 4High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 5High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 6High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 7High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 8Organize Your Data from the Big Blue Mutation Assay 2Organize Your Data from the Big Blue Mutation Assay 3
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... have marine biologists come to learn about the eye-opening characteristics ... bones of whale carcasses. With each new study, scientists ... Osedax , a genus of mouthless and gutless "bone worms" ... In the latest finding, scientists at Scripps Institution of Oceanography ...
... pilot study suggest that a virtual patient advocate (VPA) ... healthier pregnancies. Developed at Boston University School of Medicine ... is an innovative tool developed to deliver preconception care ... The study results, which are published online ...
... University professorsDavid Heeger, Joseph LeDoux, and Ruth Nussenzweighave been ... D.C.-based organization announced today. Heeger and LeDoux, ... and Department of Psychology, and Nussenzweig, a professor in ... were among the 84 new members and 21 foreign ...
Cached Biology News:Bizarre bone worms emit acid to feast on whale skeletons 2Virtual patient advocate delivers preconception care to improve pregnancy outcomes 2Virtual patient advocate delivers preconception care to improve pregnancy outcomes 33 NYU faculty elected to National Academy of Sciences 2
Lipid Phosphate Phosphohydrolase 2...
Request Info...
Chicken polyclonal to Thioredoxin domain containing 9 ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez Gene ID: 10190 Swiss Protein ID: O14530...
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Biology Products: